Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer

PURPOSE: Prostate cancer is the second leading cause of cancer death in men worldwide. Olaparib is clinically approved for the treatment prostate cancer, but cytotoxicity and off-target effects including DNA damage limit its clinical applications. In the current study, new strategies to improve the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhenwei, Dai, Zhihong, Wang, Bingwei, Gao, Yuren, Gao, Xiang, Wang, Liang, Zhou, Sihai, Yang, Liqin, Qiu, Xiaofu, Liu, Zhiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349550/
https://www.ncbi.nlm.nih.gov/pubmed/34377000
http://dx.doi.org/10.2147/OTT.S291267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349550/
https://www.ncbi.nlm.nih.gov/pubmed/34377000
http://dx.doi.org/10.2147/OTT.S291267

Ejemplares similares